Lymphopenia is an Important Prognostic Factor in Peripheral T-cell Lymphoma (NOS) Treated with Anthracycline-containing Chemotherapy

Overview

Journal J Hematol Oncol

Publisher Biomed Central

Specialties Hematology
Oncology

Date 2011 Aug 17

PMID 21843362

Citations 15

Authors

Yu Ri Kim

Jin Seok Kim

Soo Jeong Kim

Hyun Ae Jung

Seok Jin Kim

Won Seog Kim

Hye Won Lee

Hyeon Seok Eom

Seong Hyun Jeong

Joon Seong Park

June-Won Cheong

Yoo Hong Min

Affiliations

Soon will be listed here.

Abstract

Background: Peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS) is a heterogeneous group of aggressive T-cell lymphomas with poor treatment outcomes. The aim of this study was to evaluate whether lymphopenia at diagnosis would have an adverse effect on survival in patients with PTCL-NOS treated with anthracycline-containing chemotherapy.

Methods: A total of 118 patients with PTCL-NOS treated with anthracycline-containing chemotherapy from 4 Korean institutions were included.

Results: Thirty-six patients (30.5%) had a low absolute lymphocyte count (ALC, < 1.0 × 109/L) at diagnosis. Patients with lymphopenia had shorter overall survival (OS) and progression-free survival (PFS) rates compared with patients with high ALCs (P = 0.003, P = 0.012, respectively). In multivariate analysis, high-intermediate/high-risk International Prognostic Index (IPI) scores and lymphopenia were both associated with shorter OS and PFS. Treatment-related mortality was 25.0% in the low ALC group and 4.8% in the high ALC group (P = 0.003). In patients considered high-intermediate/high-risk based on IPI scores, lymphopenia was also associated with shorter OS and PFS (P = 0.002, P = 0.001, respectively).

Conclusion: This study suggests that lymphopenia could be an independent prognostic marker to predict unfavorable OS and PFS in patients with PTCL-NOS treated with anthracycline-containing chemotherapy and can be used to further stratify high-risk patients using IPI scores.

Citing Articles

Lymphopenia Caused by Virus Infections and the Mechanisms Beyond.

Guo Z, Zhang Z, Prajapati M, Li Y Viruses. 2021; 13(9).

PMID: 34578457 PMC: 8473169. DOI: 10.3390/v13091876.

Expression of telomerase reverse transcriptase in peripheral T-cell lymphoma.

Arakawa F, Miyoshi H, Yoshida N, Nakashima K, Watatani Y, Furuta T Cancer Med. 2021; 10(19):6786-6794.

PMID: 34477310 PMC: 8495278. DOI: 10.1002/cam4.4200.

Lymphopenia in Cancer Patients and its Effects on Response to Immunotherapy: an opportunity for combination with Cytokines?.

Menetrier-Caux C, Ray-Coquard I, Blay J, Caux C J Immunother Cancer. 2019; 7(1):85.

PMID: 30922400 PMC: 6437964. DOI: 10.1186/s40425-019-0549-5.

Lymphoma epidemiology in Korea and the real clinical field including the Consortium for Improving Survival of Lymphoma (CISL) trial.

Yoo K, Lee H, Suh C Int J Hematol. 2018; 107(4):395-404.

PMID: 29357080 DOI: 10.1007/s12185-018-2403-9.

Pegylated liposomal-encapsulated doxorubicin in cutaneous composite lymphoma: A case report.

Wollina U, Langner D, Hansel G, Haroske G Medicine (Baltimore). 2016; 95(43):e4796.

PMID: 27787356 PMC: 5089085. DOI: 10.1097/MD.0000000000004796.

References

Kao S, Pavlakis N, Harvie R, Vardy J, Boyer M, van Zandwijk N . High blood neutrophil-to-lymphocyte ratio is an indicator of poor prognosis in malignant mesothelioma patients undergoing systemic therapy. Clin Cancer Res. 2010; 16(23):5805-13. DOI: 10.1158/1078-0432.CCR-10-2245. View

Kim D, Baek J, Chae Y, Kim Y, Kim H, Park Y . Absolute lymphocyte counts predicts response to chemotherapy and survival in diffuse large B-cell lymphoma. Leukemia. 2007; 21(10):2227-30. DOI: 10.1038/sj.leu.2404780. View

Cox M, Nofroni I, Laverde G, Ferrari A, Amodeo R, Tatarelli C . Absolute lymphocyte count is a prognostic factor in diffuse large B-cell lymphoma. Br J Haematol. 2008; 141(2):265-8. DOI: 10.1111/j.1365-2141.2008.07028.x. View

Escalon M, Liu N, Yang Y, Hess M, Walker P, Smith T . Prognostic factors and treatment of patients with T-cell non-Hodgkin lymphoma: the M. D. Anderson Cancer Center experience. Cancer. 2005; 103(10):2091-8. DOI: 10.1002/cncr.20999. View

Cheson B, Horning S, Coiffier B, Shipp M, Fisher R, Connors J . Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol. 1999; 17(4):1244. DOI: 10.1200/JCO.1999.17.4.1244. View

Borg C, Ray-Coquard I, Philip I, Clapisson G, Bendriss-Vermare N, Menetrier-Caux C . CD4 lymphopenia as a risk factor for febrile neutropenia and early death after cytotoxic chemotherapy in adult patients with cancer. Cancer. 2004; 101(11):2675-80. DOI: 10.1002/cncr.20688. View

Plonquet A, Haioun C, Jais J, Debard A, Salles G, Bene M . Peripheral blood natural killer cell count is associated with clinical outcome in patients with aaIPI 2-3 diffuse large B-cell lymphoma. Ann Oncol. 2007; 18(7):1209-15. DOI: 10.1093/annonc/mdm110. View

Oki Y, Yamamoto K, Kato H, Kuwatsuka Y, Taji H, Kagami Y . Low absolute lymphocyte count is a poor prognostic marker in patients with diffuse large B-cell lymphoma and suggests patients' survival benefit from rituximab. Eur J Haematol. 2008; 81(6):448-53. DOI: 10.1111/j.1600-0609.2008.01129.x. View

Porrata L, Rsitow K, Inwards D, Ansell S, Micallef I, Johnston P . Lymphopenia assessed during routine follow-up after immunochemotherapy (R-CHOP) is a risk factor for predicting relapse in patients with diffuse large B-cell lymphoma. Leukemia. 2010; 24(7):1343-9. DOI: 10.1038/leu.2010.108. View

10.

Cox M, Nofroni I, Ruco L, Amodeo R, Ferrari A, La Verde G . Low absolute lymphocyte count is a poor prognostic factor in diffuse-large-B-cell-lymphoma. Leuk Lymphoma. 2008; 49(9):1745-51. DOI: 10.1080/10428190802226425. View

11.

Behl D, Ristow K, Markovic S, Witzig T, Habermann T, Colgan J . Absolute lymphocyte count predicts therapeutic efficacy of rituximab therapy in follicular lymphomas. Br J Haematol. 2007; 137(5):409-15. DOI: 10.1111/j.1365-2141.2007.06596.x. View

12.

Gallamini A, Stelitano C, Calvi R, Bellei M, Mattei D, Vitolo U . Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study. Blood. 2003; 103(7):2474-9. DOI: 10.1182/blood-2003-09-3080. View

13.

Rizvi M, Evens A, Tallman M, Nelson B, Rosen S . T-cell non-Hodgkin lymphoma. Blood. 2005; 107(4):1255-64. DOI: 10.1182/blood-2005-03-1306. View

14.

. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med. 1993; 329(14):987-94. DOI: 10.1056/NEJM199309303291402. View

15.

Vose J, Armitage J, Weisenburger D . International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol. 2008; 26(25):4124-30. DOI: 10.1200/JCO.2008.16.4558. View

16.

Porrata L, Ristow K, Habermann T, Witzig T, Inwards D, Markovic S . Absolute lymphocyte count at the time of first relapse predicts survival in patients with diffuse large B-cell lymphoma. Am J Hematol. 2009; 84(2):93-7. DOI: 10.1002/ajh.21337. View

17.

Ray-Coquard I, Cropet C, Van Glabbeke M, Sebban C, Cesne A, Judson I . Lymphopenia as a prognostic factor for overall survival in advanced carcinomas, sarcomas, and lymphomas. Cancer Res. 2009; 69(13):5383-91. PMC: 2775079. DOI: 10.1158/0008-5472.CAN-08-3845. View

18.

Huang J, Jiang W, Lin T, Huang Y, Xu R, Huang H . Absolute lymphocyte count is a novel prognostic indicator in extranodal natural killer/T-cell lymphoma, nasal type. Ann Oncol. 2010; 22(1):149-155. DOI: 10.1093/annonc/mdq314. View

19.

Gutierrez-Garcia G, Garcia-Herrera A, Cardesa T, Martinez A, Villamor N, Ghita G . Comparison of four prognostic scores in peripheral T-cell lymphoma. Ann Oncol. 2010; 22(2):397-404. DOI: 10.1093/annonc/mdq359. View

20.

Porta C, Larghi P, Rimoldi M, Totaro M, Allavena P, Mantovani A . Cellular and molecular pathways linking inflammation and cancer. Immunobiology. 2009; 214(9-10):761-77. DOI: 10.1016/j.imbio.2009.06.014. View